Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the proposed sale of Sage Therapeutics, Inc. to Supernus Pharmaceuticals, Inc., focusing on the financial implications for current shareholders and the contingent value rights associated with the transaction [1]. Company Overview - Sage Therapeutics, Inc. is involved in a proposed sale to Supernus Pharmaceuticals, Inc. Current shareholders are set to receive $8.50 per share in cash, along with a non-tradable contingent value right worth up to $3.50 per share [1]. Financial Details - The contingent value right includes three potential cash payments: - $0.50 upon the first commercial sale of the drug Zurzuvae in Japan by June 30, 2026 - $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. by December 31, 2028 - $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. by December 31, 2030 [1]. Legal Context - Monteverde & Associates PC is recognized as a top firm in securities class action services and has a successful track record in recovering money for shareholders [1].

Biogen (BIIB) reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate of $3.32.Earnings declined 18% year over year on a reported basis, owing to costs related to an upfront payment of $165 million made to Stoke Therapeutics (STOK) . BIIB entered into a collaboration agreement with STOK for the development and commercialization of the latter’s pipeline candidate, zorevunersen for treating Dravet syndrome in February. (Find the latest EPS estimates an ...

First Quarter 2025 Financial Results April 29, 2025 Safe Harbor Statement Sage Therapeutics © 2025 2 Barry Greene Chief Executive Officer Chris Benecchi Chief Operating Officer Mike Quirk • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "visio ...

Biogen (BIIB) will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's earnings beat expectations by 0.58%. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $2.24 billion and $3.34 per share, respectively. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Factors to Consider for BiogenIn the first quarter, lower sales of multiple sclerosis (“MS”) drugs are likely to have been offset by revenues ...